Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain

Pilot Phase Inclusion Criteria:

1. 18 years of age or older

2. A clinical decision was made for the patient to receive a commercial Medtronic SCSsystem (trial and implant) limited to the components for an on-label indicationprior to enrollment in the study. NOTE: Vectris™ SureScan™ MRI 1x8 subcompact andSpecify™SureScan™ MRI 2x8 leads are not eligible system components

3. Able to differentiate between pain associated with the indication for SCS implantand other types of pain, as determined by the Investigator or designee

4. Willing and able to use a personal smart phone for study surveys. NOTE: All subjectsparticipating in the study must be willing to download the InsightPro™ clinicaltrial app and maintain current software updates on their own smart phone.

5. Willing and able to provide signed and dated informed consent in English

6. Willing and able to comply with all study procedures and visits

Pilot Phase Exclusion Criteria:

1. Any active implantable neuromodulation device or system (e.g., Peripheral NerveStimulation, Sacral Neuromodulation)

2. Currently participating, or plans to participate, in another investigational studyor has a planned major medical procedure that may interfere with study procedures orconfound study results, as determined by the Investigator or designee, unlessdocumented pre-approval is provided by the sponsor

3. Major untreated or refractory psychiatric comorbidity or other progressive disease (e.g., neurodegenerative disease, heart failure, cancer) that may confound studyresults, as determined by the Investigator or designee

4. Serious drug-related behavioral issues (e.g., alcohol dependency, illegal substanceabuse), as determined by the Investigator or designee

5. Pregnant or planning on becoming pregnant

6. Involved in an injury claim under current litigation, beneficiary of an injuryclaim, or receiving worker's compensation

7. Patients with buried lead trials/implants will be excluded from this study